Inari Medical, Inc.
NARIHealthcare · Surgical & Medical Instruments & Apparatus · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | |
|---|---|---|---|---|---|---|
| Revenue | $493.6M | $383.5M | $277.0M | $139.7M | $51.1M | $6.8M |
| Operating income | −$14.0M | −$28.1M | $10.8M | $18.4M | $801,000 | −$9.1M |
| Net income | −$1.6M | −$29.3M | $9.8M | $13.8M | −$1.2M | −$10.2M |
| Total assets | $674.2M | $504.2M | $311.5M | $214.1M | $44.5M | — |
| Total liabilities | $209.3M | $87.2M | $72.3M | $13.8M | $29.5M | — |
| Equity | $464.9M | $417.0M | $239.2M | $200.3M | −$39.1M | −$39.4M |
| EPS (diluted) | $-0.03 | $-0.55 | $0.18 | $0.27 | $-0.20 | $-2.01 |
| Shares out. | 54.3M | 50.6M | 49.5M | 49.3M | 6.7M | 5.1M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2023- Operating margin
- −2.8%
- Net margin
- −0.3%
- Return on equity
- −0.4%
- Return on assets
- −0.2%
- Return on capital (ROCE)
- −2.3%
- Liabilities / assets
- 31.0%
- Debt / equity
- 0.45×
- Book value / share
- $8.56
- Revenue growth (YoY)
- 28.7%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2023- Altman Z″ (distress)
- 3.51safe
- Accruals / assets
- −5.6%clean
- Beneish M-Score
- -1.12elevated
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 warning● 5 good- Operating losses (negative operating margin)
- Reported a net loss
- Beneish M-Score elevated — earnings-manipulation screen flag
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Positive operating cash flow
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Milder Donald BPassive (13G)May 1, 2025
- Cvf, LlcPassive (13G)Feb 12, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsFeb 19, 2025
- Entered a material agreement · Regulation FD disclosureJan 6, 2025
- Results of operationsOct 28, 2024
- Director / officer change · Regulation FD disclosureJul 30, 2024
- Results of operationsJul 30, 2024
- Results of operationsApr 30, 2024
- Shareholder voteApr 25, 2024
- Results of operationsFeb 28, 2024
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SCHEDULE 13G/AMay 1, 2025
- 15-12GMar 3, 2025
- 4PRIMARY DOCUMENTFeb 19, 2025
- 4PRIMARY DOCUMENTFeb 19, 2025
- 4PRIMARY DOCUMENTFeb 19, 2025
- 4PRIMARY DOCUMENTFeb 19, 2025
- 4PRIMARY DOCUMENTFeb 19, 2025
- 4PRIMARY DOCUMENTFeb 19, 2025
- 4PRIMARY DOCUMENTFeb 19, 2025
- 4PRIMARY DOCUMENTFeb 19, 2025
- 4PRIMARY DOCUMENTFeb 19, 2025
- 4PRIMARY DOCUMENTFeb 19, 2025
- 4PRIMARY DOCUMENTFeb 19, 2025
- 4PRIMARY DOCUMENTFeb 19, 2025
- 25-NSEFeb 19, 2025